<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26831">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022215</url>
  </required_header>
  <id_info>
    <org_study_id>ME1111-2</org_study_id>
    <nct_id>NCT02022215</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ME1111 in Patients With Onychomycosis</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meiji Seika Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meiji Seika Pharma Co., Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and efficacy of high and low strength of
      ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete cure rate at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>complete cure :clear (zero %) clinical involvement of the target great toenail and mycologic cure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete or almost complete cure rate at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>complete or almost complete cure:5 % or less clinical involvement of the target great toenail and mycologic cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>Up to Week 48, Week 52, EOS</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tolerability Assessments</measure>
    <time_frame>Up to Week 48, Week 52, EOS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local Tolerability Assessments:Burning/Stinging, Pruritus, Dryness, Scaling, Erythema, General Irritation, Induration/Edema, Oozing/crusting.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>ME1111 Solution, Low strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ME1111 Solution, High strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Vehicle Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ME1111 Solution, Low strength</intervention_name>
    <description>ME1111 Solution, Low strength, applied once daily for 48 weeks</description>
    <arm_group_label>ME1111 Solution, Low strength</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ME1111 Solution, High strength</intervention_name>
    <description>ME1111 Solution, High strength, applied once daily for 48 weeks</description>
    <arm_group_label>ME1111 Solution, High strength</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Vehicle Solution</intervention_name>
    <description>Matching Vehicle Solution, applied once daily for 48 weeks</description>
    <arm_group_label>Matching Vehicle Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate distal lateral subungual onychomycosis

          -  A positive potassium hydroxide (KOH) microscopy

          -  A positive fungal culture for a dermatophyte

          -  Good general health

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Onychomycosis of the fingernails

          -  Prior use of antifungal drugs (Failure to complete the specified washout period)

          -  History of HIV, Hepatitis B or Hepatitis C

          -  Diagnosis of psoriasis or history of psoriasis

          -  Participated in any other trial of an investigational drug or device within 30 days
             or participation in a research study concurrent with this study

          -  Pregnancy/lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuharu Egawa</last_name>
    <role>Study Chair</role>
    <affiliation>Meiji Seika Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boni E. Elewski</last_name>
      <phone>205-502-9960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy R. Smith</last_name>
      <phone>619-787-5723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth G. Gross</last_name>
      <phone>858-292-8641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter K. Nahm</last_name>
      <phone>858-278-8470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Reyzelman</last_name>
      <phone>415-345-1195</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Sugarman</last_name>
      <phone>707-545-4537</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James M. Swinehart</last_name>
      <phone>303-744-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Alonso-Llamazares</last_name>
      <phone>305-225-0400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Flores</last_name>
      <phone>954-430-1097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark R. Ling</last_name>
      <phone>770-252-6900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brock A. McConnehey</last_name>
      <phone>208-685-0600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles P. Hudson</last_name>
      <phone>812-474-1234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Weisfeld</last_name>
      <phone>410-426-5508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David P. Fivenson</last_name>
      <phone>734-222-9630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Clinton Twp</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Stewart</last_name>
      <phone>586-286-7325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven E. Kempers</last_name>
      <phone>763-571-4200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Tschen</last_name>
      <phone>505-247-4220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fran E. Cook-Bolden</last_name>
      <phone>212-223-6599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John H. Tu</last_name>
      <phone>585-697-1818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Noss</last_name>
      <phone>513-247-5577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Blauvelt</last_name>
      <phone>503-245-1525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phoebe Rich</last_name>
      <phone>503-226-3376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Strout</last_name>
      <phone>843-856-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Grande</last_name>
      <phone>865-251-9963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael H. Gold</last_name>
      <phone>615-383-9660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T. Jarratt</last_name>
      <phone>512-349-9889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry M. Jones</last_name>
      <phone>979-774-5933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard A. Pollak</last_name>
      <phone>210-949-0807</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard J. Swinyer</last_name>
      <phone>801-269-0135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David C. Wilson</last_name>
      <phone>434-847-8400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>December 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
